<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>                  Enter section text here<BR>               <BR>               <BR>               <BR>                  <BR>                     image of figure 1<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     image of figure 2<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     image of figure 3<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     image of figure 4<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     image of figure 5<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1 Updated Adjuvant Treatment of Early Breast Cancer<BR>                     <BR>                        In a multicenter study enrolling over 8,000 postmenopausal women <BR>with resected, receptor-positive early breast cancer, one of the following <BR>treatments was randomized in a double-blind manner: <BR>                        Option 1: <BR>    A.     Tamoxifen for 5 years <BR>    B.     Letrozole for 5 <BR>years <BR>    C.     Tamoxifen for 2 years followed by letrozole for 3 years <BR><BR>    D.     Letrozole for 2 years followed by tamoxifen for 3 years <BR>                        Option 2: <BR>    A.     Tamoxifen for 5 years<BR>    B.     Letrozole for 5 <BR>years <BR>                        The study in the adjuvant setting, BIG 1-98 was designed to answer two <BR>primary questions: whether letrozole for 5 years was superior to tamoxifen for 5 <BR>years (Primary Core Analysis) and whether switching endocrine treatments at 2 <BR>years was superior to continuing the same agent for a total of 5 years <BR>(Sequential Treatments Analysis). Selected baseline characteristics for the <BR>study population are shown in Table 5. The primary endpoint of this trial was <BR>disease-free survival (DFS) (i.e., interval between randomization and earliest <BR>occurrence of a local, regional, or distant recurrence, or invasive <BR>contralateral breast cancer, or death from any cause). The secondary endpoints <BR>were overall survival (OS), systemic disease-free survival (SDFS), invasive <BR>contralateral breast cancer, time to breast cancer recurrence (TBR) and time to <BR>distant metastasis (TDM). <BR>                        The Primary Core Analysis (PCA) included all patients and all follow-up in <BR>the monotherapy arms in both randomization options, but follow-up in the two <BR>sequential treatments arms was truncated 30 days after switching treatments. The <BR>PCA was conducted at a median treatment duration of 24 months and a median <BR>follow-up of 26 months. Letrozole was superior to tamoxifen in all endpoints <BR>except overall survival and contralateral breast cancer [e.g., DFS: hazard <BR>ratio, HR 0.79; 95% CI (0.68, 0.92); P = 0.002; SDFS: <BR>HR 0.83; 95% CI (0.70, 0.97); TDM: HR 0.73; 95% CI (0.60, 0.88); OS: HR 0.86; <BR>95% CI (0.70, 1.06). <BR>                        In 2005, based on recommendations by the independent Data Monitoring <BR>Committee, the tamoxifen arms were unblinded and patients were allowed to <BR>complete initial adjuvant therapy with letrozole (if they had received tamoxifen <BR>for at least 2 years) or to start extended adjuvant treatment with letrozole (if <BR>they had received tamoxifen for at least 4.5 years) if they remained alive and <BR>disease-free. In total, 632 patients crossed to letrozole or another aromatase <BR>inhibitor. Approximately 70% (448) of these 632 patients crossed to letrozole to <BR>complete initial adjuvant therapy and most of these crossed in years 3 to 4. All <BR>of these patients were in Option 1. A total of 184 patients started extended <BR>adjuvant therapy with letrozole (172 patients) or with another aromatase <BR>inhibitor (12 patients). To explore the impact of this selective crossover, <BR>results from analyses censoring follow-up at the date of the selective crossover <BR>(in the tamoxifen arm) are presented for the Monotherapy Arms Analysis (MAA). <BR><BR>                        The PCA allowed the results of letrozole for 5 years compared with tamoxifen <BR>for 5 years to be reported in 2005 after a median follow-up of only 26 months. <BR>The design of the PCA is not optimal to evaluate the effect of letrozole after a <BR>longer time (because follow-up was truncated in two arms at around 25 months). <BR>The Monotherapy Arms Analysis (ignoring the two sequential treatment arms) <BR>provided follow-up equally as long in each treatment and did not over-emphasize <BR>early recurrences as the PCA did. The MAA thus provides the clinically <BR>appropriate updated efficacy results in answer to the first primary question, <BR>despite the confounding of the tamoxifen reference arm by the selective <BR>crossover to letrozole. The updated results for the MAA are summarized in Table <BR>6. Median follow-up for this analysis is 73 months. <BR>                        The Sequential Treatments Analysis (STA) addresses the second primary <BR>question of the study. The primary analysis for the Sequential Treatments <BR>Analysis (STA) was from switch (or equivalent time-point in monotherapy arms) + <BR>30 days (STA-S) with a two-sided test applied to each pair-wise comparison at <BR>the 2.5% level. Additional analyses were conducted from randomization (STA-R) <BR>but these comparisons (added in light of changing medical practice) were <BR>under-powered for efficacy. <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="801" ID="i802b6fbc-758a-4342-876f-a76dce01e48b"><BR>                           <caption>Table 5: Adjuvant Study - Patient and Disease Characteristics (ITT <BR>Population) </caption><BR>                           <col width="28%"/><BR>                           <col width="17%"/><BR>                           <col width="18%"/><BR>                           <col width="18%"/><BR>                           <col width="18%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Primary Core Analysis </content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(PCA)</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Monotherapy Arms Analysis</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(MAA)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Characteristic</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 4,003</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 4,007</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 2,463</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 2,459</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Age (median, years)</td><BR>                                 <td>61</td><BR>                                 <td>61</td><BR>                                 <td>61</td><BR>                                 <td>61</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Age range (years)</td><BR>                                 <td>38 to 89</td><BR>                                 <td>39 to 90</td><BR>                                 <td>38 to 88</td><BR>                                 <td>39 to 90</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Hormone receptor status (%)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;ER+ and/or PgR+</td><BR>                                 <td>99.7</td><BR>                                 <td>99.7</td><BR>                                 <td>99.7</td><BR>                                 <td>99.7</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Both unknown</td><BR>                                 <td>0.3</td><BR>                                 <td>0.3</td><BR>                                 <td>0.3</td><BR>                                 <td>0.3</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Nodal status (%)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Node negative</td><BR>                                 <td>52</td><BR>                                 <td>52</td><BR>                                 <td>50</td><BR>                                 <td>52</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Node positive</td><BR>                                 <td>41</td><BR>                                 <td>41</td><BR>                                 <td>43</td><BR>                                 <td>41</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Nodal status unknown</td><BR>                                 <td><BR>                                    <content styleCode="bold">7</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">7</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">7</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">7</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Prior adjuvant chemotherapy <BR>(%)</td><BR>                                 <td>24</td><BR>                                 <td>24</td><BR>                                 <td>24</td><BR>                                 <td>24</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="944" ID="ib22c4d02-476d-4c53-81be-f35573768165"><BR>                           <caption>Table 6: Updated Adjuvant Study Results - Monotherapy Arms Analysis <BR>(Median Follow-up 73 Months) </caption><BR>                           <col width="24%"/><BR>                           <col width="7%"/><BR>                           <col width="15%"/><BR>                           <col width="7%"/><BR>                           <col width="15%"/><BR>                           <col width="8%"/><BR>                           <col width="14%"/><BR>                           <col width="8%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = <BR>2,463</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = <BR>2,459</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Hazard <BR>Ratio</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Events</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">5-year <BR>rate</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Events</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">5-year <BR>rate</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">(95%CI)</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content><BR>                                    </content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Disease-free survival<linkHtml href="#footnote-7">*</linkHtml><BR>                                 </td><BR>                                 <td>ITT</td><BR>                                 <td>445 (18.1)</td><BR>                                 <td>87.4</td><BR>                                 <td>500 (20.3)</td><BR>                                 <td>84.7</td><BR>                                 <td>0.87 (0.76, 0.99)</td><BR>                                 <td>0.03</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>Censor</td><BR>                                 <td>445</td><BR>                                 <td>87.4</td><BR>                                 <td>483</td><BR>                                 <td>84.2</td><BR>                                 <td>0.84 (0.73, 0.95)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;0 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td>165</td><BR>                                 <td>92.2</td><BR>                                 <td>189</td><BR>                                 <td>90.3</td><BR>                                 <td>0.88 (0.72, 1.09)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;1 to 3 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td>151</td><BR>                                 <td>85.6</td><BR>                                 <td>163</td><BR>                                 <td>83</td><BR>                                 <td>0.85 (0.68, 1.06)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;&gt; = 4 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td>123</td><BR>                                 <td>71.2</td><BR>                                 <td>142</td><BR>                                 <td>62.6</td><BR>                                 <td>0.81 (0.64, 1.03)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Adjuvant chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td>119</td><BR>                                 <td>86.4</td><BR>                                 <td>150</td><BR>                                 <td>80.6</td><BR>                                 <td>0.77 (0.60, 0.98)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;No chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td>326</td><BR>                                 <td>87.8</td><BR>                                 <td>350</td><BR>                                 <td>86.1</td><BR>                                 <td>0.91 (0.78, 1.06)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Systemic DFS<linkHtml href="#footnote-8">&#8224;</linkHtml><BR>                                 </td><BR>                                 <td>ITT</td><BR>                                 <td>401</td><BR>                                 <td>88.5</td><BR>                                 <td>446</td><BR>                                 <td>86.6</td><BR>                                 <td>0.88 (0.77,1.01)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Time to distant metastasis<linkHtml href="#footnote-9">&#8225;</linkHtml><BR>                                 </td><BR>                                 <td>ITT</td><BR>                                 <td>257</td><BR>                                 <td>92.4</td><BR>                                 <td>298</td><BR>                                 <td>90.1</td><BR>                                 <td>0.85 (0.72, 1.00)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Adjuvant chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td>84</td><BR>                                 <td>-</td><BR>                                 <td>109</td><BR>                                 <td>-</td><BR>                                 <td>0.75 (0.56-1.00)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;No chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td>173</td><BR>                                 <td>-</td><BR>                                 <td>189</td><BR>                                 <td>-</td><BR>                                 <td>0.90 (0.73,1.11)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Distant DFS<linkHtml href="#footnote-10">&#167;</linkHtml><BR>                                 </td><BR>                                 <td>ITT</td><BR>                                 <td>385</td><BR>                                 <td>89</td><BR>                                 <td>432</td><BR>                                 <td>87.1</td><BR>                                 <td>0.87 (0.76,1.00)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Contralateral breast cancer</td><BR>                                 <td>ITT</td><BR>                                 <td>34</td><BR>                                 <td>99.2</td><BR>                                 <td>44</td><BR>                                 <td>98.6</td><BR>                                 <td>0.76 (0.49, 1.19)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Overall survival</td><BR>                                 <td>ITT</td><BR>                                 <td>303</td><BR>                                 <td>91.8</td><BR>                                 <td>343</td><BR>                                 <td>90.9</td><BR>                                 <td>0.87 (0.75, 1.02)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>Censor</td><BR>                                 <td>303</td><BR>                                 <td>91.8</td><BR>                                 <td>338</td><BR>                                 <td>90.1</td><BR>                                 <td>0.82 (0.70, 0.96)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;0 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td>107</td><BR>                                 <td>95.2</td><BR>                                 <td>121</td><BR>                                 <td>94.8</td><BR>                                 <td>0.90 (0.69.1.16)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;1 to 3 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td>99</td><BR>                                 <td>90.8</td><BR>                                 <td>114</td><BR>                                 <td>90.6</td><BR>                                 <td>0.81(0.62,1.06)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;&gt; = 4 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td>92</td><BR>                                 <td>80.2</td><BR>                                 <td>104</td><BR>                                 <td>73.6</td><BR>                                 <td>0.86 (0.65, 1.14)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Adjuvant chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td>76</td><BR>                                 <td>91.5</td><BR>                                 <td>96</td><BR>                                 <td>88.4</td><BR>                                 <td>0.79 (0.58, 1.06)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;No chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td>227</td><BR>                                 <td>91.9</td><BR>                                 <td>247</td><BR>                                 <td>91.8</td><BR>                                 <td>0.91 (0.76, 1.08)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>ITT analysis ignores selective crossover in tamoxifen arms. <BR>Censored <BR>analysis censors follow-up at the date of selective crossover in 632 patients <BR>who crossed to letrozole or another aromatase inhibitor after the tamoxifen arms <BR>were unblinded in 2005.<BR>                        *Disease-free survival: Interval from randomization to earliest event of <BR>invasive loco-regional recurrence, distant metastasis, invasive contralateral <BR>breast cancer or death without a prior event.<BR><BR>                        †Systemic disease-free survival: Interval from randomization to invasive <BR>regional recurrence, distant metastasis or death without a prior cancer event.‡Time to distant metastasis: Interval from randomization to distant <BR>metastasis.§Distant disease-free survival: Interval from randomization to earlier event <BR>of relapse in a distant site or death from any cause.<BR><BR>                        <BR><BR>                        Figure 1 shows the Kaplan-Meier curves for Disease-Free Survival Monotherapy <BR>Analysis. <BR><BR>                        <BR>                        <BR>                           <BR>                        <BR>                        <BR>                        Figure 1: Disease-Free Survival (Median follow-up 73 <BR>months, ITT Approach) <BR>                        The medians of overall survival for both arms were not reached for the <BR>Monotherapy Arms Analysis (MAA). There was no statistically significant <BR>difference in overall survival. The hazard ratio for survival in the letrozole <BR>arm compared to the tamoxifen arm was 0.87, with 95% CI (0.75, 1.02) (see Table 6). <BR>                        There were no significant differences in DFS, OS, SDFS and Distant DFS from <BR>switch in the Sequential Treatments Analysis with respect to either monotherapy <BR>(e.g., [Tamoxifen 2 years followed by] letrozole 3 years vs. tamoxifen beyond 2 <BR>years, DFS HR 0.89; 97.5% CI 0.68, 1.15 and [letrozole 2 years followed by] <BR>tamoxifen 3 years vs. letrozole beyond 2 years, DFS HR 0.93; 97.5% CI 0.71, <BR>1.22). There were no significant differences in DFS, OS, SDFS and Distant DFS <BR>from randomization in the Sequential Treatments Analyses. <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2 Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 24 Months<BR>                     <BR>                        A double-blind, randomized, placebo-controlled trial of letrozole <BR>was performed in over 5,100 postmenopausal women with receptor-positive or <BR>unknown primary breast cancer who were disease free after 5 years of adjuvant <BR>treatment with tamoxifen. <BR>                        The planned duration of treatment for patients in the study was 5 years, but <BR>the trial was terminated early because of an interim analysis showing a <BR>favorable letrozole effect on time without recurrence or contralateral breast <BR>cancer. At the time of unblinding, women had been followed for a median of 28 <BR>months, 30% of patients had completed 3 or more years of follow-up and less than <BR>1% of patients had completed 5 years of follow-up. <BR>                        Selected baseline characteristics for the study population are shown in Table <BR>7. <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="657" ID="i70f7d2ae-5170-498a-8886-1fc69974abf5"><BR>                           <caption>Table 7: Selected Study Population Demographics (Modified ITT <BR>Population) </caption><BR>                           <col width="33%"/><BR>                           <col width="33%"/><BR>                           <col width="32%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Baseline Status</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = <BR>2,582</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Placebo</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = <BR>2,586</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Hormone Receptor Status</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;ER+ and/or PgR+</td><BR>                                 <td>98</td><BR>                                 <td>98</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Both Unknown</td><BR>                                 <td>2</td><BR>                                 <td>2</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Nodal Status <BR>(%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Node Negative</td><BR>                                 <td>50</td><BR>                                 <td>50</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Node Positive</td><BR>                                 <td>46</td><BR>                                 <td>46</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Nodal Status Unknown</td><BR>                                 <td>4</td><BR>                                 <td>4</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Chemotherapy</content><BR>                                 </td><BR>                                 <td>46</td><BR>                                 <td>46</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> <BR>                        Table 8 shows the study results. Disease-free survival was measured as the <BR>time from randomization to the earliest event of loco-regional or distant <BR>recurrence of the primary disease or development of contralateral breast cancer <BR>or death. DFS by hormone receptor status, nodal status and adjuvant chemotherapy <BR>were similar to the overall results. Data were premature for an analysis of <BR>survival. <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="804" ID="i7ea5f4b6-2a2e-4cee-81c5-3dc0222b60c5"><BR>                           <caption>Table 8: Extended Adjuvant Study Results </caption><BR>                           <col width="27%"/><BR>                           <col width="18%"/><BR>                           <col width="18%"/><BR>                           <col width="18%"/><BR>                           <col width="18%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole </content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = <BR>2,582</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Placebo </content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = <BR>2,586</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Hazard Ratio <BR><br/>(95% CI)</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content>-Value</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Disease Free <BR>Survival (DFS)<linkHtml href="#footnote-11">*</linkHtml> <BR>Events</content><BR>                                 </td><BR>                                 <td>122 (4.7%)</td><BR>                                 <td>193 (7.5%)</td><BR>                                 <td>0.62 (0.49, 0.78)<linkHtml href="#footnote-12">&#8224;</linkHtml><BR>                                 </td><BR>                                 <td>0.00003</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Local Breast Recurrence</td><BR>                                 <td>9</td><BR>                                 <td>22</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Local Chest Wall Recurrence</td><BR>                                 <td>2</td><BR>                                 <td>8</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Regional Recurrence</td><BR>                                 <td>7</td><BR>                                 <td>4</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Distant Recurrence</td><BR>                                 <td>55</td><BR>                                 <td>92</td><BR>                                 <td>0.61 (0.44 to 0.84)</td><BR>                                 <td>0.003</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Contralateral Breast Cancer</td><BR>                                 <td>19</td><BR>                                 <td>29</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Deaths Without Recurrence <BR>or Contralateral Breast Cancer</td><BR>                                 <td>30</td><BR>                                 <td>38</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table>CI = confidence interval for hazard ratio. Hazard ratio of less than 1.0 <BR>indicates difference in favor of letrozole (lesser risk of recurrence); hazard <BR>ratio greater than 1.0 indicates difference in favor of placebo (higher risk of <BR>recurrence with letrozole). <BR><BR><BR><BR><BR>                        P-value based on <BR>stratified logrank test.<BR><BR>                        *First event of loco-regional recurrence, distant relapse, contralateral <BR>breast cancer or death from any cause.†Analysis stratified by receptor status, nodal status and prior adjuvant <BR>chemotherapy (stratification factors as at randomization). <BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.3 Updated Analyses of Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 60 Months<BR>                     <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="839" ID="ifb91878d-455c-4b36-8ca2-62bb11a8b05e"><BR>                           <caption>Table 9: Update of Extended Adjuvant Study Results</caption><BR>                           <col width="44%"/><BR>                           <col width="13%"/><BR>                           <col width="12%"/><BR>                           <col width="17%"/><BR>                           <col width="13%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole </content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 2,582 </content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Placebo </content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">N = 2,586 </content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Hazard Ratio<linkHtml href="#footnote-13">*</linkHtml><BR>                                       <br/>(95% <BR>CI)</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content>-Value<linkHtml href="#footnote-14">&#8224;</linkHtml><BR>                                    </content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Disease Free <BR>Survival (DFS) events<linkHtml href="#footnote-15">&#8225;</linkHtml><BR>                                    </content><BR>                                 </td><BR>                                 <td>344 (13.3)</td><BR>                                 <td>402 (15.5)</td><BR>                                 <td>0.89 (0.77, 1.03)</td><BR>                                 <td>0.12</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Breast cancer recurrence</content><BR>                                    </paragraph>(Protocol <BR>definition of DFS events<linkHtml href="#footnote-16">&#167;</linkHtml>)</td><BR>                                 <td>209</td><BR>                                 <td>286</td><BR>                                 <td>0.75 (0.63, 0.89)</td><BR>                                 <td>0.001</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Local Breast Recurrence</td><BR>                                 <td>15</td><BR>                                 <td>44</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Local Chest Wall Recurrence</td><BR>                                 <td>6</td><BR>                                 <td>14</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Regional Recurrence</td><BR>                                 <td>10</td><BR>                                 <td>8</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Distant Recurrence</td><BR>                                 <td>140</td><BR>                                 <td>167</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Distant recurrence (first or <BR>subsequent events)</td><BR>                                 <td>142</td><BR>                                 <td>169</td><BR>                                 <td>0.88 (0.70,1.10)</td><BR>                                 <td>0.246</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Contralateral Breast Cancer</td><BR>                                 <td>37</td><BR>                                 <td>53</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Deaths Without Recurrence <BR>or Contralateral Breast Cancer </td><BR>                                 <td>135</td><BR>                                 <td>116</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>*Adjusted by receptor status, nodal status and prior chemotherapy.†Stratified logrank test, stratified by receptor status, nodal status and <BR>prior chemotherapy.‡DFS events defined as earliest of loco-regional recurrence, distant <BR>metastasis, contralateral breast cancer or death from any cause, and ignoring <BR>switches to letrozole in 60% of the placebo arm.§Protocol definition does not include deaths from any cause.<BR><BR>                        Updated analyses were conducted at a median follow-up of 62 <BR>months. In the letrozole arm, 71% of the patients were treated for a least 3 <BR>years and 58% of patients completed at least 4.5 years of extended adjuvant <BR>treatment. After the unblinding of the study at a median follow-up of 28 months, <BR>approximately 60% of the selected patients in the placebo arm opted to switch to <BR>letrozole. <BR>                        In this updated analysis shown in Table 9, letrozole significantly reduced <BR>the risk of breast cancer recurrence or contralateral breast cancer compared <BR>with placebo (HR 0.75; 95% CI 0.63, 0.89; P = 0.001). <BR>However, in the updated DFS analysis (interval between randomization and <BR>earliest event of loco-regional recurrence, distant metastasis, contralateral <BR>breast cancer or death from any cause) the treatment difference was heavily <BR>diluted by 60% of the patients in the placebo arm switching to letrozole and <BR>accounting for 64% of the total placebo patient- years of follow-up. Ignoring <BR>these switches, the risk of DFS event was reduced by a non-significant 11% (HR <BR>0.89; 95% CI 0.77, 1.03). There was no significant difference in distant <BR>disease-free survival or overall survival. <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.4 First-Line Treatment of Advanced Breast Cancer<BR>                     <BR>                        A randomized, double-blind, multinational trial compared <BR>letrozole 2.5 mg with tamoxifen 20 mg in 916 postmenopausal patients with <BR>locally advanced (Stage IIIB or loco-regional recurrence not amenable to <BR>treatment with surgery or radiation) or metastatic breast cancer. Time to <BR>progression (TTP) was the primary endpoint of the trial. Selected baseline <BR>characteristics for this study are shown in Table 10. <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="727" ID="ib7d9d5b7-3b9f-46c0-8067-4700952bf745"><BR>                           <caption>Table 10: Selected Study Population Demographics </caption><BR>                           <col width="41%"/><BR>                           <col width="29%"/><BR>                           <col width="29%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Baseline Status</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = <BR>458</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = <BR>458</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Stage of <BR>Disease</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;IIIB</td><BR>                                 <td>6%</td><BR>                                 <td>7%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;IV</td><BR>                                 <td>93%</td><BR>                                 <td>92%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Receptor <BR>Status</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;ER and PgR Positive</td><BR>                                 <td>38%</td><BR>                                 <td>41%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;ER or PgR Positive</td><BR>                                 <td>26%</td><BR>                                 <td>26%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Both Unknown</td><BR>                                 <td>34%</td><BR>                                 <td>33%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;ER<sup>&#8211;</sup> or <BR>PgR<sup>&#8211;</sup>/Other Unknown</td><BR>                                 <td>&lt; 1%</td><BR>                                 <td>0</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Previous <BR>Antiestrogen Therapy</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Adjuvant</td><BR>                                 <td>19%</td><BR>                                 <td>18%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;None</td><BR>                                 <td>81%</td><BR>                                 <td>82%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Dominant Site of <BR>Disease</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Soft Tissue</td><BR>                                 <td>25%</td><BR>                                 <td>25%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Bone</td><BR>                                 <td>32%</td><BR>                                 <td>29%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Viscera</td><BR>                                 <td>43%</td><BR>                                 <td>46%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> Letrozole was superior to tamoxifen in TTP and rate of objective tumor <BR>response (see Table 11). <BR>                        Table 11 summarizes the results of the trial, with a total median follow-up <BR>of approximately 32 months. (All analyses are unadjusted and use 2-sided P-values.) <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="949" ID="ib7b26b4f-53ab-4a8d-830d-2b109803c68a"><BR>                           <caption>Table 11: Results of First-Line Treatment of Advanced Breast Cancer <BR></caption><BR>                           <col width="31%"/><BR>                           <col width="22%"/><BR>                           <col width="22%"/><BR>                           <col width="23%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">2.5 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 453</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Tamoxifen</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">20 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 454</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Hazard or Odds</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Ratio (95% CI)</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content>-Value (2-Sided)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Median Time to <BR>Progression</content><BR>                                 </td><BR>                                 <td>9.4 months</td><BR>                                 <td>6 months</td><BR>                                 <td>0.72 (0.62, 0.83)<linkHtml href="#footnote-17">*</linkHtml><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="italics">P</content> &lt; <BR>0.0001</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Objective Response <BR>Rate</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;(CR + PR)</td><BR>                                 <td>145 (32%)</td><BR>                                 <td>95 (21%)</td><BR>                                 <td>1.77 (1.31, 2.39)<linkHtml href="#footnote-18">&#8224;</linkHtml><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="italics">P</content> = <BR>0.0002</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;(CR)</td><BR>                                 <td>42 (9%)</td><BR>                                 <td>15 (3%)</td><BR>                                 <td>2.99 (1.63, 5.47)<linkHtml href="#footnote-18">&#8224;</linkHtml><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="italics">P</content> = <BR>0.0004</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Duration of <BR>Objective Response</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;Median</td><BR>                                 <td>18 months</td><BR>                                 <td>16 months</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>(N = 145)</td><BR>                                 <td>(N = 95)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Overall <BR>Survival</content><BR>                                 </td><BR>                                 <td>35 months</td><BR>                                 <td>32 months</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>(N = 458)</td><BR>                                 <td>(N = 458)</td><BR>                                 <td><BR>                                    <content styleCode="italics">P</content> = <BR>0.5136<linkHtml href="#footnote-19">&#8225;</linkHtml><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>*Hazard ratio †Odds ratio ‡Overall logrank test <BR>Figure 2 shows the Kaplan-Meier curves for TTP.<BR><BR>                        <BR>                        <BR><BR>                        Figure 2: Kaplan-Meier Estimates of Time to <BR>Progression (Tamoxifen Study) <BR>                        Table12 shows results in the subgroup of women who had received prior <BR>antiestrogen adjuvant therapy, Table 13, results by disease site and Table 14, <BR>the results by receptor status. <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="947" ID="ife7fd43b-e571-4901-815a-6dd5ffecfa3d"><BR>                           <caption>Table 12: Efficacy in Patients Who Received Prior Antiestrogen <BR>Therapy</caption><BR>                           <col width="31%"/><BR>                           <col width="22%"/><BR>                           <col width="22%"/><BR>                           <col width="23%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Variable</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Letrozole</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Tamoxifen</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">20 mg</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">N = <BR>84</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">N = <BR>83</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Median Time to <BR>Progression </content>(95% CI)</td><BR>                                 <td>8.9 months (6.2, 12.5)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>5.9 months (3.2, 6.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Hazard Ratio for TTP (95% <BR>CI)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>0.60 (0.43, 0.84)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Objective Response <BR>Rate</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;(CR + PR)</td><BR>                                 <td>22 (26%)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>7 (8%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Odds Ratio for Response <BR>(95% CI)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>3.85 (1.50, 9.60)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> Hazard ratio less than 1 or odds ratio greater than 1 favors letrozole; hazard ratio greater than 1 or odds ratio less than 1 favors tamoxifen.<BR><BR>                        <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="719" ID="idce85042-714e-4c6f-89be-076a0a877f40"><BR>                           <caption>Table 13: Efficacy by Disease Site</caption><BR>                           <col width="40%"/><BR>                           <col width="29%"/><BR>                           <col width="29%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Letrozole</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Tamoxifen</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">20 <BR>mg</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Dominant Disease Site</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">Soft Tissue:</content><BR>                                 </td><BR>                                 <td>N = 113</td><BR>                                 <td>N = 115</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Median TTP</td><BR>                                 <td>12.1 months</td><BR>                                 <td>6.4 months</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Objective Response Rate</td><BR>                                 <td>50%</td><BR>                                 <td>34%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Bone:</content><BR>                                 </td><BR>                                 <td>N = 145</td><BR>                                 <td>N = 131</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Median TTP</td><BR>                                 <td>9.5 months</td><BR>                                 <td>6.3 months</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Objective Response Rate</td><BR>                                 <td>23%</td><BR>                                 <td>15%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Viscera:</content><BR>                                 </td><BR>                                 <td>N = 195</td><BR>                                 <td>N = 208</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Median TTP</td><BR>                                 <td>8.3 months</td><BR>                                 <td>4.6 months</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Objective Response <BR>Rate</td><BR>                                 <td>28%</td><BR>                                 <td>17%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="719" ID="i3915bed8-7852-4926-8c2e-bfb745c288cb"><BR>                           <caption>Table 14: Efficacy by Receptor Status</caption><BR>                           <col width="40%"/><BR>                           <col width="29%"/><BR>                           <col width="29%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Variable</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Letrozole</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Tamoxifen</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">20 <BR>mg</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Receptor <BR>Positive</content><BR>                                 </td><BR>                                 <td>N = 294</td><BR>                                 <td>N = 305</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Median Time to Progression (95% <BR>CI)</td><BR>                                 <td>9.4 months (8.9, 11.8)</td><BR>                                 <td>6 months (5.1, 8.5)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Hazard Ratio for TTP (95% <BR>CI)</td><BR>                                 <td>0.69 (0.58, 0.83)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Objective Response Rate (CR + <BR>PR)</td><BR>                                 <td>97 (33%)</td><BR>                                 <td>66 (22%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Odds Ratio for Response (95% <BR>CI)</td><BR>                                 <td>1.78 (1.20, 2.60)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Receptor <BR>Unknown</content><BR>                                 </td><BR>                                 <td>N = 159</td><BR>                                 <td>N = 149</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Median Time to Progression (95% <BR>CI)</td><BR>                                 <td>9.2 months (6.1, 12.3)</td><BR>                                 <td>6 months (4.1, 6.4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Hazard Ratio for TTP (95% <BR>CI)</td><BR>                                 <td>0.77 (0.60, 0.99)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Objective Response Rate (CR + <BR>PR)</td><BR>                                 <td>48 (30%)</td><BR>                                 <td>29 (20%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Odds Ratio for Response <BR>(95% CI)</td><BR>                                 <td>1.79 (1.10, 3.00)</td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Hazard ratio less than 1 or odds ratio greater than 1 favors letrozole;<BR>hazard ratio greater than 1 or odds ratio less than 1 favors tamoxifen.<BR>                        <BR>                           <BR><BR>                        <BR>                        Figure 3 shows the Kaplan-Meier curves for survival.<BR>                        <BR>                           <BR>                        <BR>                        Figure 3: Survival by Randomized Treatment <BR>Arm<BR>                        <BR>                           Legend: Randomized letrozole: n = 458, events 57%, <BR>median overall survival 35 months (95% CI 32 to 38 months) <BR>                        Randomized tamoxifen: n = 458, events 57%, median overall survival 32 months <BR>(95% CI 28 to 37 months) <BR>                        Overall logrank P=0.5136 (i.e., there was no <BR>significant difference between treatment arms in overall survival). <BR>                        The median overall survival was 35 months for the letrozole group and 32 <BR>months for the tamoxifen group, with a P-value <BR>0.5136. Study design allowed patients to cross over upon progression to the <BR>other therapy. Approximately 50% of patients crossed over to the opposite <BR>treatment arm and almost all patients who crossed over had done so by 36 months. <BR>The median time to crossover was 17 months (letrozole to tamoxifen) and 13 <BR>months (tamoxifen to letrozole). In patients who did not cross over to the <BR>opposite treatment arm, median survival was 35 months with letrozole (n = 219, <BR>95% Cl 29 to 43 months) vs. 20 months with tamoxifen (n = 229, 95% Cl 16 to 26 <BR>months). <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.5 Second-Line Treatment of Advanced Breast Cancer<BR>                     <BR>                        Letrozole was initially studied at doses of 0.1 mg to 5.0 mg <BR>daily in six non-comparative Phase I/II trials in 181 postmenopausal <BR>estrogen/progesterone receptor positive or unknown advanced breast cancer <BR>patients previously treated with at least antiestrogen therapy. Patients had <BR>received other hormonal therapies and also may have received cytotoxic therapy. <BR>Eight (20%) of 40 patients treated with letrozole 2.5 mg daily in Phase I/II <BR>trials achieved an objective tumor response (complete or partial response). <BR>                        Two large randomized, controlled, multinational (predominantly European) <BR>trials were conducted in patients with advanced breast cancer who had progressed <BR>despite antiestrogen therapy. Patients were randomized to letrozole 0.5 mg <BR>daily, letrozole 2.5 mg daily, or a comparator (megestrol acetate 160 mg daily <BR>in one study; and aminoglutethimide 250 mg b.i.d. with corticosteroid <BR>supplementation in the other study). In each study over 60% of the patients had <BR>received therapeutic antiestrogens, and about one-fifth of these patients had <BR>had an objective response. The megestrol acetate controlled study was <BR>double-blind; the other study was open label. Selected baseline characteristics <BR>for each study are shown in Table 15. <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="727" ID="i2aba9cf9-4ba8-4302-8a06-18bd03649945"><BR>                           <caption>Table 15: Selected Study Population Demographics </caption><BR>                           <col width="41%"/><BR>                           <col width="29%"/><BR>                           <col width="29%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Parameter</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Megestrol Acetate</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">Study</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Aminoglutethimide</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">Study</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">No. of <BR>Participants</content><BR>                                 </td><BR>                                 <td>552</td><BR>                                 <td>557</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Receptor <BR>Status</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;ER/PR Positive</td><BR>                                 <td>57%</td><BR>                                 <td>56%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;ER/PR Unknown</td><BR>                                 <td>43%</td><BR>                                 <td>44%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Previous <BR>Therapy</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Adjuvant Only</td><BR>                                 <td>33%</td><BR>                                 <td>38%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Therapeutic +/- Adj.</td><BR>                                 <td>66%</td><BR>                                 <td>62%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Sites of <BR>Disease</content><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Soft Tissue</td><BR>                                 <td>56%</td><BR>                                 <td>50%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Bone</td><BR>                                 <td>50%</td><BR>                                 <td>55%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;&#160;&#160;&#160;Viscera</td><BR>                                 <td>40%</td><BR>                                 <td>44%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> <BR>                        Confirmed objective tumor response (complete response plus partial response) <BR>was the primary endpoint of the trials. Responses were measured according to the <BR>Union Internationale Contre le Cancer (UICC) criteria and verified by <BR>independent, blinded review. All responses were confirmed by a second evaluation <BR>4 to 12 weeks after the documentation of the initial response. <BR>                        Table 16 shows the results for the first trial, with a minimum follow-up of <BR>15 months, that compared letrozole 0.5 mg, letrozole 2.5 mg, and megestrol <BR>acetate 160 mg daily. (All analyses are unadjusted.) <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="946" ID="i01c0b428-25cf-4707-8346-1c2d5160217b"><BR>                           <caption>Table 16: Megestrol Acetate Study Results </caption><BR>                           <col width="32%"/><BR>                           <col width="22%"/><BR>                           <col width="22%"/><BR>                           <col width="22%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">0.5 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 188</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">2.5 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 174</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Megestrol</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Acetate</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 190</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Objective Response <BR>(CR + PR)</content><BR>                                 </td><BR>                                 <td>22 (11.7%)</td><BR>                                 <td>41 (23.6%)</td><BR>                                 <td>31 (16.3%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Median Duration of <BR>Response</content><BR>                                 </td><BR>                                 <td>552 days</td><BR>                                 <td>(Not reached)</td><BR>                                 <td>561 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Median Time to <BR>Progression</content><BR>                                 </td><BR>                                 <td>154 days</td><BR>                                 <td>170 days</td><BR>                                 <td>168 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Median <BR>Survival</content><BR>                                 </td><BR>                                 <td>633 days</td><BR>                                 <td>730 days</td><BR>                                 <td>659 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Odds Ratio for <BR>Response</content><BR>                                 </td><BR>                                 <td>letrozole 2.5: letrozole 0.5 <BR>= 2.33</td><BR>                                 <td>letrozole 2.5: megestrol = <BR>1.58</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>(95% CI: 1.32, 4.17); <content styleCode="italics">P</content> = 0.004<linkHtml href="#footnote-20">*</linkHtml><BR>                                 </td><BR>                                 <td>(95% CI: 0.94, 2.66); <content styleCode="italics">P</content> = 0.08<linkHtml href="#footnote-20">*</linkHtml><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Relative Risk of <BR>Progression</content><BR>                                 </td><BR>                                 <td>letrozole 2.5: letrozole 0.5 <BR>= 0.81</td><BR>                                 <td>letrozole 2.5: megestrol = <BR>0.77</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>(95% CI: 0.63, 1.03); <content styleCode="italics">P</content> = 0.09<linkHtml href="#footnote-20">*</linkHtml><BR>                                 </td><BR>                                 <td>(95% CI: 0.60, 0.98), <content styleCode="italics">P</content> = 0.03<linkHtml href="#footnote-20">*</linkHtml><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>*two-sided P-value<BR><BR>                        The Kaplan-Meier curves for progression for the megestrol acetate study are <BR>shown in Figure 4. <BR><BR>                        <BR>                        <BR>                           <BR>                        <BR>                        <BR>                        Figure 4: Kaplan-Meier Estimates of Time to <BR>Progression (Megestrol Acetate Study)<BR>                        The results for the study comparing letrozole to aminoglutethimide, with a <BR>minimum follow-up of 9 months, are shown in Table 17. (Unadjusted analyses are <BR>used.) <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="1" width="940" ID="i30b9683d-5125-4404-872e-bbb7e98ee351"><BR>                           <caption>Table 17: Aminoglutethimide Study Results </caption><BR>                           <col width="32%"/><BR>                           <col width="22%"/><BR>                           <col width="22%"/><BR>                           <col width="22%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">0.5 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 193</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Letrozole</content><BR>                                    </paragraph><BR>                                    <paragraph><BR>                                       <content styleCode="bold">2.5 mg</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N = 185</content><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Aminoglutethimide</content><BR>                                    </paragraph><BR>                                    <content styleCode="bold">N <BR>= 179</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Objective Response <BR>(CR + PR)</content><BR>                                 </td><BR>                                 <td>34 (17.6%)</td><BR>                                 <td>34 (18.4%)</td><BR>                                 <td>22 (12.3%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Median Duration of <BR>Response</content><BR>                                 </td><BR>                                 <td>619 days</td><BR>                                 <td>706 days</td><BR>                                 <td>450 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Median Time to <BR>Progression</content><BR>                                 </td><BR>                                 <td>103 days</td><BR>                                 <td>123 days</td><BR>                                 <td>112 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Median <BR>Survival</content><BR>                                 </td><BR>                                 <td>636 days </td><BR>                                 <td>792 days</td><BR>                                 <td>592 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Odds Ratio for <BR>Response</content><BR>                                 </td><BR>                                 <td>letrozole 2.5:</td><BR>                                 <td>letrozole 2.5:</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>letrozole 0.5 = 1.05</td><BR>                                 <td>aminoglutethimide = 1.61</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph>(95% CI: 0.62, 1.79); </paragraph><BR>                                    <content styleCode="italics">P</content> = 0.85<linkHtml href="#footnote-21">*</linkHtml><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph>(95% CI: 0.90, 2.87); </paragraph><BR>                                    <content styleCode="italics">P</content> = 0.11<linkHtml href="#footnote-21">*</linkHtml><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Relative Risk of <BR>Progression</content><BR>                                 </td><BR>                                 <td>letrozole 2.5:</td><BR>                                 <td>letrozole 2.5:</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td>letrozole 0.5 = 0.86</td><BR>                                 <td>aminoglutethimide = 0.74</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <br/><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph>(95% CI: 0.68, 1.11); </paragraph><BR>                                    <content styleCode="italics">P</content> = 0.25<linkHtml href="#footnote-21">*</linkHtml><BR>                                 </td><BR>                                 <td><BR>                                    <paragraph>(95% CI: 0.57, 0.94), </paragraph><BR>                                    <content styleCode="italics">P</content> = 0.02<linkHtml href="#footnote-21">*</linkHtml><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR>                        *two-sided P-value<BR>The Kaplan-Meier curves for progression for the aminoglutethimide study is shown <BR>in Figure 5.<BR><BR>                        <BR>                        Figure 5: Kaplan-Meier Estimates of Time to <BR>Progression (Aminoglutethimide Study)<BR>                        <BR>                        <BR><BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>